MX2020007401A - Novedosa combinacion y uso de anticuerpos. - Google Patents

Novedosa combinacion y uso de anticuerpos.

Info

Publication number
MX2020007401A
MX2020007401A MX2020007401A MX2020007401A MX2020007401A MX 2020007401 A MX2020007401 A MX 2020007401A MX 2020007401 A MX2020007401 A MX 2020007401A MX 2020007401 A MX2020007401 A MX 2020007401A MX 2020007401 A MX2020007401 A MX 2020007401A
Authority
MX
Mexico
Prior art keywords
immune cell
region
riib
antibody
receptor
Prior art date
Application number
MX2020007401A
Other languages
English (en)
Inventor
Bjórn FRENDÉUS
Ingrid Teige
Linda Mårtensson
Mark Cragg
Stephen Beers
Ali Roghanian
Robert Oldham
Original Assignee
Bioinvent Int Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1800395.4A external-priority patent/GB201800395D0/en
Priority claimed from GBGB1800461.4A external-priority patent/GB201800461D0/en
Application filed by Bioinvent Int Ab filed Critical Bioinvent Int Ab
Publication of MX2020007401A publication Critical patent/MX2020007401A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describe el uso de una primera molecula de anticuerpo que se une específicamente a Fc?RIIb a traves de su region Fab, pero carece de la region Fc o tiene una union reducida a los receptores de Fc? a traves de su region Fc, para usar en combinacion con una segunda molecula de anticuerpo que se une especificamente a un receptor presente en una celula inmunitaria, en donde la celula inmunitaria es una celula inmunitaria que suprime la inmunidad contra el cancer, dicha segunda molecula de anticuerpo tiene una region Fc que se une a al menos un receptor de Fc? activador, y en donde la union de la segunda molecula de anticuerpo al receptor en la celula inmunitaria provoca el agotamiento y/o desactivacion de la celula inmunitaria en el tratamiento de un cancer negativo a Fc?RIIb en un paciente, asi como composiciones farmaceuticas y kits que comprenden estas con las moleculas de anticuerpos, y metodos para tratar el cancer con el uso de estos dos anticuerpos.
MX2020007401A 2018-01-10 2019-01-10 Novedosa combinacion y uso de anticuerpos. MX2020007401A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1800395.4A GB201800395D0 (en) 2018-01-10 2018-01-10 Novel combination and use of antibodies
GBGB1800461.4A GB201800461D0 (en) 2018-01-11 2018-01-11 Novel combination and use of antibodies
PCT/EP2019/050566 WO2019138005A2 (en) 2018-01-10 2019-01-10 Novel combination and use of antibodies

Publications (1)

Publication Number Publication Date
MX2020007401A true MX2020007401A (es) 2020-11-09

Family

ID=65236986

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007401A MX2020007401A (es) 2018-01-10 2019-01-10 Novedosa combinacion y uso de anticuerpos.

Country Status (10)

Country Link
US (2) US12371498B2 (es)
EP (1) EP3737698A2 (es)
JP (2) JP7800852B2 (es)
KR (1) KR20200108286A (es)
CN (2) CN120617499A (es)
AU (1) AU2019207767B2 (es)
BR (1) BR112020013925A2 (es)
CA (1) CA3088856A1 (es)
MX (1) MX2020007401A (es)
WO (1) WO2019138005A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220259309A1 (en) * 2019-07-17 2022-08-18 Bioinvent International Ab Antibody combinations for treatment of cancer in specific patients
IL272389A (en) * 2020-01-30 2021-08-31 Yeda Res & Dev Kits containing antibodies to PD-L1 and their uses in therapy
EP3919077A1 (en) 2020-06-04 2021-12-08 BioInvent International AB Model for prediction of tolerability issues in connection with intravenous administration of therapeutic antibodies
WO2021245238A1 (en) 2020-06-04 2021-12-09 Bioinvent International Ab Improving antibody tolerability associated with intravenous administration
CN112480259B (zh) * 2021-02-05 2021-05-04 百奥赛图(北京)医药科技股份有限公司 抗tnfr2抗体及其用途
IL305469A (en) * 2021-03-09 2023-10-01 Bioinvent Int Ab Novel combinations of antibodies and uses thereof
TW202336033A (zh) 2022-03-07 2023-09-16 瑞典商生物創新國際有限公司 抗體之新穎組合及用途
KR20250122541A (ko) 2022-10-25 2025-08-13 사이즈믹 테라퓨틱, 인코포레이티드. 변이체 IgG FC 폴리펩티드 및 그 용도
WO2024178273A1 (en) * 2023-02-24 2024-08-29 The Regents Of The University Of California Methods for epigenetic analysis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2196002T3 (es) 1991-07-25 2003-12-16 Idec Pharma Corp Anticuerpos recombinantes para terapia humana.
US20150344575A1 (en) * 2003-08-14 2015-12-03 Macrogenics, Inc. FcGammaRIIB Specific Antibodies and Methods of Use Thereof
WO2006073921A2 (en) 2004-12-30 2006-07-13 The Rockefeller University Compositions and methods for enhanced dendritic cell maturation and function
WO2008002933A2 (en) 2006-06-26 2008-01-03 Macrogenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
GB2526139A (en) 2014-05-15 2015-11-18 Biolnvent Internat Ab Medicaments, uses and methods
US9382321B2 (en) 2014-11-26 2016-07-05 Adventis Health System/Sunbelt, Inc. Effector-deficient anti-CD32A antibodies
CA3005986A1 (en) 2015-11-23 2017-06-01 Innate Pharma Cd39 vascular isoform targeting agents
RU2018126297A (ru) * 2015-12-18 2020-01-22 Новартис Аг Антитела, нацеленные на cd32b, и способы их применения
KR20190017735A (ko) * 2016-04-07 2019-02-20 캔써 리서치 테크놀로지 리미티드 종양 특이적 세포 고갈을 위한 항 cd25 fc 감마 수용체 이중특이적 항체

Also Published As

Publication number Publication date
JP7800852B2 (ja) 2026-01-16
BR112020013925A2 (pt) 2020-12-01
US12371498B2 (en) 2025-07-29
EP3737698A2 (en) 2020-11-18
AU2019207767A1 (en) 2020-07-09
WO2019138005A2 (en) 2019-07-18
WO2019138005A3 (en) 2019-09-19
CN120617499A (zh) 2025-09-12
KR20200108286A (ko) 2020-09-17
JP2024026237A (ja) 2024-02-28
JP2021510299A (ja) 2021-04-22
CN111683969A (zh) 2020-09-18
US20200362036A1 (en) 2020-11-19
RU2020126449A (ru) 2022-02-10
US20260116981A1 (en) 2026-04-30
CA3088856A1 (en) 2019-07-18
AU2019207767B2 (en) 2025-09-18

Similar Documents

Publication Publication Date Title
MX2020007401A (es) Novedosa combinacion y uso de anticuerpos.
CL2020003179A1 (es) (divisional de solicitud 713-2015) anticuerpos anti-cd3, moleculas de union a antígeno biespecificas que se unen a cd3 y cd20; y usos de los mismos.
AR120515A2 (es) Conjugado de enzimas terapéuticas
CO2017005650A2 (es) Anticuerpos anti-interleucina-33
BR112019022495A2 (pt) Conjugados de anticorpo que compreendem agonista de receptor similar a toll e terapias de combinação
CL2017000250A1 (es) Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso
EA200970210A1 (ru) Prlr-специфическое антитело и его применения
BR112021008060A2 (pt) Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento
CL2025000404A1 (es) Anticuerpo anti-lilrb1 y usos del mismo
AR077724A1 (es) Anticuerpos humanos de alta afinidad contra pcsk9
CL2024003681A1 (es) Conjugado de anticuerpo anti-b7h3-fármaco y uso del mismo
MX2021005151A (es) Novedosas moleculas de anticuerpos anti-tnfr2 agonistas.
CL2012002428A1 (es) Anticurpos de dominio (dab) que se une a cd 28 e inhibe la union de cd28 a cd80 y/o cd86 y no reacciona en forma cruzada con ctla4; uso del anticuerpo para tratar una enfermedad inmune o relacionada con un injerto; composicion farmaceutica que lo comprende.
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
CO2020013833A2 (es) Anticuerpo anti-muerte programada-ligando 1 y su uso
BR112021021645A2 (pt) Anticorpos anti-hvem e uso dos mesmos.
AR086984A1 (es) Anticuerpo anti-cxcr4 con funciones efectoras y su uso en el tratamiento del cancer
CO2021015254A2 (es) Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y métodos de uso de estos
MX2021008268A (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r.
MX394735B (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
UY37757A (es) Composiciones, procedimientos y/o kits que comprenden un dominio extracelular de cd38 humano recombinante
CL2022002520A1 (es) Anticuerpos anti-sea de muc1
MX2024015391A (es) Molecula de union a antigeno que se une especificamente a dll3 y cd3, y su uso farmaceutico
MX2022000657A (es) Combinaciones de anticuerpos para el tratamiento del cancer en pacientes especificos.
BR112021016596A2 (pt) Anticorpo anti-pd-l1 e uso do mesmo